Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
996 | 2824 | 41.5 | 92% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | FAS | Author keyword | 130 | 21% | 19% | 539 |
2 | FAS LIGAND | Author keyword | 94 | 29% | 10% | 278 |
3 | AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME | Author keyword | 77 | 77% | 2% | 53 |
4 | FASL | Author keyword | 44 | 28% | 5% | 135 |
5 | CD95 | Author keyword | 42 | 25% | 5% | 146 |
6 | SOLUBLE FAS | Author keyword | 30 | 50% | 2% | 43 |
7 | ALPS UNIT | Address | 23 | 100% | 0% | 10 |
8 | CANALE SMITH SYNDROME | Author keyword | 17 | 100% | 0% | 8 |
9 | FAS ANTIGEN | Author keyword | 15 | 30% | 1% | 42 |
10 | SFAS | Author keyword | 15 | 38% | 1% | 30 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | FAS | 130 | 21% | 19% | 539 | Search FAS | Search FAS |
2 | FAS LIGAND | 94 | 29% | 10% | 278 | Search FAS+LIGAND | Search FAS+LIGAND |
3 | AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME | 77 | 77% | 2% | 53 | Search AUTOIMMUNE+LYMPHOPROLIFERATIVE+SYNDROME | Search AUTOIMMUNE+LYMPHOPROLIFERATIVE+SYNDROME |
4 | FASL | 44 | 28% | 5% | 135 | Search FASL | Search FASL |
5 | CD95 | 42 | 25% | 5% | 146 | Search CD95 | Search CD95 |
6 | SOLUBLE FAS | 30 | 50% | 2% | 43 | Search SOLUBLE+FAS | Search SOLUBLE+FAS |
7 | CANALE SMITH SYNDROME | 17 | 100% | 0% | 8 | Search CANALE+SMITH+SYNDROME | Search CANALE+SMITH+SYNDROME |
8 | FAS ANTIGEN | 15 | 30% | 1% | 42 | Search FAS+ANTIGEN | Search FAS+ANTIGEN |
9 | SFAS | 15 | 38% | 1% | 30 | Search SFAS | Search SFAS |
10 | SOLUBLE FAS LIGAND | 14 | 46% | 1% | 23 | Search SOLUBLE+FAS+LIGAND | Search SOLUBLE+FAS+LIGAND |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CD95 LIGAND | 168 | 54% | 8% | 214 |
2 | APO 1 | 94 | 76% | 2% | 66 |
3 | CD95 | 79 | 33% | 7% | 196 |
4 | COUNTERATTACK | 72 | 64% | 3% | 71 |
5 | SYNDROME ALPS | 68 | 82% | 1% | 40 |
6 | LYMPHOPROLIFERATIVE SYNDROME | 67 | 37% | 5% | 148 |
7 | CONFER IMMUNE PRIVILEGE | 66 | 57% | 3% | 79 |
8 | PATHWAY GENES FAS | 61 | 95% | 1% | 20 |
9 | DEATH FACTOR | 54 | 39% | 4% | 109 |
10 | ANTI FAS | 54 | 49% | 3% | 80 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Targeting the Fas/FasL system in Rheumatoid Arthritis therapy: Promising or risky? | 2015 | 1 | 66 | 48% |
Apoptosis by death factor | 1997 | 3829 | 78 | 33% |
The Many Roles of FAS Receptor Signaling in the Immune System | 2009 | 316 | 99 | 38% |
CD95's deadly mission in the immune system | 2000 | 1091 | 89 | 33% |
Activation-induced cell death in T cells | 2003 | 302 | 116 | 47% |
Fas ligand-induced apoptosis | 1999 | 493 | 183 | 55% |
THE FAS DEATH FACTOR | 1995 | 3453 | 130 | 50% |
New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome | 2012 | 17 | 46 | 72% |
Mature T lymphocyte apoptosis - Immune regulation in a dynamic and unpredictable antigenic environment | 1999 | 682 | 317 | 32% |
CD95, BIM and T cell homeostasis | 2009 | 89 | 60 | 45% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ALPS UNIT | 23 | 100% | 0.4% | 10 |
2 | INTERNAL MED MOL CYTOL | 6 | 80% | 0.1% | 4 |
3 | MOL DEV SECT | 4 | 47% | 0.2% | 7 |
4 | IMMUNOGENET G0300 | 4 | 75% | 0.1% | 3 |
5 | TUMOR IMMUNOL PROGRAM | 3 | 10% | 1.0% | 29 |
6 | MOL BIOL DIS | 2 | 40% | 0.1% | 4 |
7 | DEV MOL TARGET DRUGS | 1 | 17% | 0.3% | 8 |
8 | COMPOSANTES INNEES REPONSE IMMUNITAIRE DIFF | 1 | 100% | 0.1% | 2 |
9 | GENETROVE | 1 | 50% | 0.1% | 2 |
10 | TRANSPLANT IMMUNOBIOL UNIT | 1 | 50% | 0.1% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000216853 | SFAS APO 1//ACUTE RELAPSE//AMYLOID PEPTIDE A BETA |
2 | 0.0000126632 | NECROPTOSIS//RIP3//NECROSTATIN 1 |
3 | 0.0000104474 | EMI U 9922//UNITE PHYSIOPATHOL INFECT LENTIVIRALES//DIPARTIMENTO IGIENE MED PREVENT SANITA PUBBL |
4 | 0.0000101370 | SHOCK TRAUMA S//SURG ALPERT MED//A549 CELL APOPTOSIS |
5 | 0.0000083649 | M65//M30//M65 ELISA |
6 | 0.0000083506 | CD3 ZETA//ORAL BIOL ORAL MED//ZETA CHAIN |
7 | 0.0000082136 | CASP10//CASP8//CASPASE 10 |
8 | 0.0000068300 | NEW ZEALAND MICE//RHEUMATOL CLIN MED//MRL LPR MICE |
9 | 0.0000068216 | TRAIL//DR5//TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND |
10 | 0.0000063803 | DCR3//DECOY RECEPTOR 3//TL1A |